Wanhua Starts Production of IPDI in China

China’s Wanhua Chemical Group has successfully started up its new aliphatic diisocyanate (ADI) plant in Yantai Industrial Park. The facility produces isophorone diisocyanate (IPDI), which will be marketed under the brand name Wannate. Capacity details were not disclosed.

Wanhua said it is the first company in Asia to manufacture the complete chain from isophorone through to IPDI. It also lays claim to being China’s sole ADI producer.

Steven Sun, general manager of Wanhua’s ADI business unit, said IPDI now completes the company’s “very competitive” ADI portfolio and will satisfy the global market’s need for high-performance products.

Due to its primary and secondary isocyanate groups, the compound allows controlled poly-addition with polyol co-reactants, providing the possibility to design molecular structures for specific materials.

IPDI’s major applications are waterborne PU dispersions, adhesives and UV resins. The IPDI trimer can be used in non-yellowing, high-performance PU coatings for various end-uses such as automotive refinish.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.